x
10/2021 Portfolio

ITHERA RECEIVES EIC ACCELERATOR GRANT

Congratulations to our medical device portfolio company iThera Medical for being successfully funded by the EIC Accelerator Program, Europe’s largest and most selective public funding program for breakthrough innovation projects.
Through this project, iThera Medical will translate its proprietary optoacoustic imaging technology (MSOT) from research use to routine clinical application, providing physicians worldwide with a powerful new diagnostic tool. This will enable improved diagnosis and treatment monitoring for diseases related to inflammation, fibrosis and cancer.

More information can be found in the press release under the following link.

More about iThera Medical

09/2021 Team

TEAM OFFSITE IN BERLIN

 
EAT. BERLIN. SLEEP. REPEAT.

For 4 days we did just that at this year’s major offsite in Berlin. Besides many culinary highlights, we explored this great city in very different ways and presented our new employee benefits @ OCCIDENT to the team.

It was wonderful to spend time together again after the many months of limited contact, vaccinated and tested, and to get to know our four “new” employees better in private as well.

09/2021 Portfolio

MK2 BIOTECHNOLOGIES IN THE CURRENT PLATTFORM LIFE SCIENCES

Thank you, Plattform Life Sciences, for introducing our latest portfolio company. With its technology platform, mk2 Bio­technologies can produce peptides also for price-sensitive industrial applications. For the first time, there is the potential to use peptides in antibiotic substitutes, sustainable crop protection agents, sustainable preservatives for food, but also in pharmaceuticals against diseases such as cancer or AIDS, which are currently very difficult to treat or cure.
The market for biocatalysts is already a multi-billion market with double-digit growth rates, so we look forward to seeing the concrete results of the collaborations with industry that are already underway.

More about OCCIDENT can be found in the fact sheet on page 98, and details about mk2 Biotechnologies can be found on page 111 of the Plattform Life Sciences (only in German language).

09/2021 About

CELEBRATING SUCCESS TOGETHER

As an investor and entrepreneurial partner, we support our founders over many years. We are therefore thrilled to see the fantastic development they are going through and the great successes they are celebrating.
We are now happy together with our Swiss portfolio companies Resistell and hemotune about their recognition at #9 and #37 at the Top 100 Swiss Startup Awards. It is also fantastic to see Versantis and Lunaphore recognized among the Top 25 Scale-ups.

More about Resistell
More about hemotune

More about the Top 100 Swiss Startup Awards

08/2021 About

WE SHAPE OUR TOMORROW

OCCIDENT invests not only in innovations, but also in talents. For 7 years now, we have been supporting CO-OPERAID’s Talents project, a scholarship program for young people from very poor families in Bangladesh, Cambodia and Laos. We are proud that with our support so far 54 students have gained access to higher education; already 15 of them have success­fully completed it and are improving our tomorrow in a sustainable way as doctors, lawyers or kindergarten teachers.

We look forward to supporting more talents in the future and giving them the opportunity for an education.

More about the Talents project

07/2021 Portfolio

INVESTMENT IN MK2 BIOTECHNOLOGIES

OCCIDENT invests in industrial biotech for the first time and participates as lead investor in Munich-based startup mk2 Biotechnologies, which focuses on the development and production of peptides. With the multi-million seed funding, the company accelerates its further growth and aims for additional development milestones towards industrializing its new peptide production platform. This revolutionary, scalable synthesis technology platform enables the production of authentic peptides, regardless of their physical or chemical properties, at large scale and low cost.

More information can be found in the press release under the following link.

More about mk2 Biotechnologies

06/2021 Portfolio

INSPHERO FORMS CONSORTIUM WITH LEADING PHARMACEUTICAL COMPANIES

Our portfolio company InSphero has formed a pre-competitive consortium with Pfizer, Sanofi, Merck and Genentech to better investigate potential negative side effects of new drugs on the liver at an early stage. Drug-induced liver damage is often the reason why the development of a new drug is discontinued.
 

The safety of new drugs is typically assessed in animal studies prior to the start of a clinical trial, which are not always reliable and should be reduced if possible. The consortium therefore aims to perform these studies on 3D micro tissues from animals and humans to provide a validated in vitro liver model and improve the ability to predict the risk of drug-indiced liver injury from new drug candidates.
 

More about

06/2021 Portfolio

SUCCESSFUL PRODUKT DEVELOPMENT AT IOP

Congratulations to our portfolio company Implandata Opthalmic Products (IOP) on two great achievements. Within a few weeks, the company announced that it had received both the European CE Mark certification and the American FDA Breakthrough Devices Designation for its EYEMATE system.

The innovative EYEMATE implant allows continuous monitoring of intraocular pressure in glaucoma patients and thus represents an important component for the optimal and efficient treatment of glaucoma in the future.

More about CE Mark

More about FDA Breakthrough Devices Designation

06/2021 Portfolio

RESISTELL STARTS PERFORMANCE EVALUATION STUDY

Starting the Performance Evaluation Study in June 2021, our portfolio company Resistell has reached a major milestone in the development of its phenotypic antibiotic susceptibility test based on the nanomotion technology. The study is being conducted at the Lausanne University Hospital (CHUV).

Since our initial investment in 2018, the company has always kept track of its goals to develop the world’s fastest antibiotic susceptibility test. We are now more than enthusiastic to see this technology being brought a major step closer to the commercial use.

More about

Show more